We searched PubMed on Dec 1, 2016, for publications written in English or French, using the keywords: “sleeping sickness”, “Trypanosoma brucei gambiense”, “Trypanosoma brucei rhodesiense”, “CATT”, “suramin”, “pentamidine”, “melarsoprol”, “eflornithine”, “tsetse”, “Glossina”, or “human African trypanosomiasis”. Results were limited to those published between 2010 and 2016. Among the almost 3000 references, we selected those we judged relevant, prioritising those reporting applied research. An
SeminarHuman African trypanosomiasis
Introduction
Human African trypanosomiasis is a neglected tropical disease that occurs in sub-Saharan Africa, within the distributional limits of the vector, the tsetse fly. Two forms of the disease exist: the slow-progressing form, caused by Trypanosoma brucei gambiense, which is endemic in western and central Africa; and, the faster-progressing form, caused by Trypanosoma brucei rhodesiense, found in eastern and southern Africa.1
Since the beginning of the 20th century, human African trypanosomiasis has killed millions of people. Today, the disease is rare, thanks to large-scale and efficient deployment of an—albeit incomplete—arsenal of control tools. Yet, cases are reported from more than 20 countries in Africa, where the disease causes substantial morbidity among the affected rural populations, and continues to pose the threat of severe epidemics.2 In a globalised world, cases are also diagnosed outside endemic African countries among travellers, tourists, expatriates, and migrants.3 In this Seminar, we discuss the epidemiology, cause, clinical features, diagnosis, and treatment of human African trypanosomiasis, and touch on epidemiological surveillance and methods of control and elimination.
Section snippets
Epidemiology
The trypanosomes that cause human African trypanosomiasis are classically transmitted by the bite of blood-sucking tsetse flies (Diptera, genus Glossina). T brucei gambiense can also be transmitted congenitally.4, 5, 6 Other routes of transmission are possible but poorly documented, and are thought to be very rare (eg, sexual, laboratory accidents, blood transfusion, and organ transplantation).6, 7, 8, 9
In the early 20th century, devastating epidemics occurred in, among other places, Uganda,
Parasite and vector
T brucei belongs to the Trypanosomatidae family of exclusively parasitic organisms found in vertebrates and insects worldwide.23 These unicellular parasites have co-evolved with their hosts to such an extent that most are commensal rather than pathogenic.24 T brucei includes three morphologically indistinguishable subspecies (figure 2): T brucei brucei, which causes animal African trypanosomiasis, and is not infective to human beings, whereas T brucei rhodesiense and T brucei gambiense can
Clinical features
The clinical presentation of human African trypa-nosomiasis depends on the T brucei subspecies, host response, and disease stage. Variations of virulence and pathogenicity are attributed to different strains of parasite.44, 45 Generally, both forms of the disease lead to death if untreated; although, for T brucei gambiense disease, healthy carriers and self-cure have been described.46 T brucei rhodesiense disease is typically acute, progressing to second-stage disease within a few weeks, and
Diagnosis
Clinical signs and symptoms of human African trypanosomiasis are unspecific and can easily be mistaken for those of other diseases; thus, they are often insufficient for diagnosis.
Reliable serodiagnostic tests exist only for T brucei gambiense infection, and are based on the detection of specific antibodies. The card agglutination test for trypanosomiasis (CATT),62 developed almost 40 years ago, has been pivotal in the control of T brucei gambiense disease. CATT can be done with blood collected
Treatment
Five drugs are routinely used in the treatment of human African trypanosomiasis: pentamidine and suramin to treat first-stage disease, and melarsoprol, eflornithine, and nifurtimox for second-stage disease. All are donated by the manufacturers, and WHO ensures their worldwide distribution free of charge. The drugs can be obtained directly from WHO in Geneva or from the few institutes that stock them (appendix).3 This accessibility means treatment of human African trypanosomiasis is unaffected
Epidemiological surveillance
Surveillance is crucial for control of human African trypanosomiasis because of the disease's focal distribution, occurrence in remote rural areas, and capacity to re-emerge when control activities are relaxed. Control operations are resource-intensive and therefore require careful targeting. Surveillance is carried out by national control programmes, with support from WHO and other partners. Field data are collected through both active and passive case detection, and are assembled, harmonised,
Control and elimination
In the absence of a vaccine or chemoprophylaxis, human African trypanosomiasis is controlled through case detection and treatment, and, to a lesser extent, vector control.
For T brucei gambiense human African trypanosomiasis, the most effective control strategy is case finding and treatment, which reduces the human reservoir and thus decreases T brucei transmission. Cases of T brucei gambiense disease are detected through active screening campaigns by mobile teams, consisting of up to eight
Conclusions
Human African trypanosomiasis has long been a typical neglected tropical disease, characterised by suboptimal control tools and inadequate funding. Over the past 15 years, thanks to the efforts of a broad range of stakeholders, the situation has changed. Today, human African trypanosomiasis is a rare disease that is targeted for elimination. Drugs are available for free thanks to donations of the manufacturers, low-cost rapid diagnostic tests and vector control tools are on the market; safe
Search strategy and selection criteria
References (147)
- et al.
Possible cases of sexual and congenital transmission of sleeping sickness
Lancet
(2004) Antigenic variation in African trypanosomes
Mol Biochem Parasitol
(2014)- et al.
Central nervous system involvement in African trypanosomiasis: presence of anti-galactocerebroside antibodies in patients' cerebrospinal fluid
Trans R Soc Trop Med Hyg
(2000) - et al.
A semi-quantitative ELISA for detection of Trypanosoma brucei gambiense specific antibodies in serum and cerebrospinal fluid of sleeping sickness patients
Acta Trop
(1998) - et al.
Mechanisms of CNS invasion and damage by parasites
Handb Clin Neurol
(2013) - et al.
The duality of sleeping sickness: focusing on sleep
Sleep Med Rev
(2001) - et al.
Polysomnography as a diagnosis and post-treatment follow-up tool in human African trypanosomiasis: a case study in an infant
J Neurol Sci
(2011) - et al.
Clinical aspects of 2541 patients with second stage human African trypanosomiasis
Acta Trop
(2006) - et al.
Cardiac involvement in African and American trypanosomiasis
Lancet Infect Dis
(2008) - et al.
Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study
Lancet Glob Health
(2014)